This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Crucell | |
|---|---|
| Name | Crucell |
| Type | Public (former) |
| Fate | Acquired by Johnson & Johnson |
| Founded | 1993 |
| Defunct | 2011 (merged into Janssen Vaccines & Prevention BV) |
| Headquarters | Leiden, Netherlands |
| Industry | Biotechnology |
| Products | Vaccines, monoclonal antibodies, viral vectors |
| Key people | Jan Steijaert; Pieter van den Berg |
Crucell Crucell was a biotechnology company headquartered in Leiden, Netherlands, focused on vaccine development, monoclonal antibodies, and viral vector platforms. Founded in the 1990s, it grew through research collaborations and acquisitions to become a notable player in infectious disease vaccines before being acquired by Johnson & Johnson in 2011. Crucell worked with academic institutions, pharmaceutical companies, and public health organizations on products targeting influenza, hepatitis, and emerging pathogens.
Crucell originated from technology spun out of Leiden University Medical Center and Infectious Diseases Research Institute collaborations, with early ties to researchers from University of Amsterdam and Erasmus MC. In the late 1990s and 2000s Crucell expanded via acquisitions, integrating assets from companies such as Genzyme-affiliated units and partnering with firms including Baxter International and Novartis. Strategic milestones included listing on the Euronext Amsterdam exchange, licensing agreements with GlaxoSmithKline and Sanofi, and a high-profile acquisition by Johnson & Johnson that transferred Crucell into the Janssen Pharmaceuticals family and ultimately into Janssen Vaccines & Prevention BV.
Crucell developed vaccines and biologics using multiple proprietary platforms: PER.C6 cell line, adenoviral vectors, and monoclonal antibody production. The PER.C6 platform, originating from research at Leiden University Medical Center, was used to manufacture viral vectors for products targeting influenza and Ebola virus candidates; it competed with platforms from Vero cell, CHO cell, and MDCK cell manufacturers. Crucell pursued seasonal and pandemic influenza vaccines, hepatitis B vaccine candidates, and adenovirus-based immunotherapies, with programs that overlapped with offerings from Novavax, Sanofi Pasteur, GlaxoSmithKline Vaccines, and MedImmune.
Crucell maintained R&D collaborations with academic centers such as Pasteur Institute, Imperial College London, Karolinska Institute, and Harvard School of Public Health, and with industry partners including Merck & Co. and Boehringer Ingelheim. Research focused on vector design, antigen expression, adjuvantation, and scale-up of PER.C6-derived processes. Clinical development programs advanced candidates through phases of trials in coordination with regulatory agencies including European Medicines Agency and U.S. Food and Drug Administration, while preclinical studies drew on models developed at institutions like Rocky Mountain Laboratories and National Institutes of Health laboratories.
Originally a Dutch public company, Crucell’s governance included a supervisory board and executive committee with investors from venture capital firms and strategic pharmaceutical partners. Major stakeholders over time included institutional investors from funds associated with ABN AMRO, Roche-linked interests, and later majority ownership by Johnson & Johnson following the acquisition. Post-acquisition, Crucell’s assets were organized within Janssen Vaccines & Prevention BV, aligning with Janssen Pharmaceuticals and Johnson & Johnson Innovation units.
Manufacturing sites were based in Leiden and other European locations, integrating bioprocessing suites for PER.C6 and mammalian cell culture comparable to facilities operated by Novartis Vaccines, GlaxoSmithKline, and Baxter International. Crucell invested in biosafety level-compliant production spaces and collaborated with contract manufacturing organizations such as Catalent and Lonza for fill-finish and scaling. The company emphasized GMP certification and capacity for rapid scale-up in response to pandemic influenza scenarios discussed with agencies like World Health Organization.
Crucell navigated regulatory pathways with the European Medicines Agency and the U.S. Food and Drug Administration for clinical trial approvals and product licensure. Safety evaluations for PER.C6-derived products addressed concerns similar to those reviewed in applications to Committee for Medicinal Products for Human Use and in discussions with national competent authorities such as Dutch Health and Youth Care Inspectorate. Pharmacovigilance plans were established consistent with directives from European Commission and post-market surveillance frameworks used by manufacturers like Sanofi and Pfizer.
Crucell entered collaborative agreements with multinational firms and public health entities including GlaxoSmithKline, Sanofi Pasteur, Baxter International, and Bartha HPAI program partners. It engaged with global health organizations such as the World Health Organization, participated in consortia with European Commission research initiatives, and worked with academic partners including University of Oxford and Johns Hopkins Bloomberg School of Public Health. Collaborations also extended to biotechnology firms like Genzyme and vaccine innovators including Protein Sciences Corporation and Vaxinnate to advance platform technologies and clinical development.
Category:Biotechnology companies of the Netherlands Category:Vaccine manufacturers